Retatrutide Research

Retatrutide Chemical Identity: What Can Actually Be Verified

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

Retatrutide is commonly listed under CAS 2381089-83-2 with a molecular weight near 4,731 Da. Neither resolves to a PubChem record. Searches for retatrutide, LY3437943 and the CAS all return nothing. The identifiers come from supplier and reference sources rather than a primary database.

Key facts

Development code
LY3437943
Reported CAS
2381089-83-2 (no PubChem record)
Reported MW
~4,731.33 Da
Reported formula
C221H342N46O68 (sources disagree)
PubChem entry
None findable
Primary reference
Coskun, Cell Metab 2022 (PMID 35985340)
Not to be confused with
Tirzepatide, LY3298176

What is actually verifiable

Less than for any other compound in this library. Searching PubChem for retatrutide, LY3437943 or LY-3437943 returns nothing, and CAS 2381089-83-2 does not resolve there either. That is unusual for a compound with Phase 3 data and a filing date, and it means the molecular weight and formula quoted everywhere trace to supplier catalogues and reference aggregators rather than to a primary chemical database.

Sources disagree on the formula

The commonly quoted figure is 4,731.33 Da for C221H342N46O68. At least one reference source gives C228H350N48O66 at approximately 4,894.58 Da instead. Both cannot be right. Where a compound has a settled database entry this kind of disagreement does not arise, and its presence here is a direct consequence of the absent entry.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The identifier this category had wrong

Until this revision, these articles cited PubChem CID 156588324 as retatrutide. That record returns 4813 Da for C225H348N48O68, and its synonyms include Zepbound, tirzepatidum and 'Tirzepatide sodium salt (LY3298176)'. It is tirzepatide. The compound retatrutide is most often compared against, and the one it most needs to be distinguished from. The citation has been removed.

What can be relied on instead

Coskun and colleagues published the discovery and characterisation of LY3437943 in Cell Metabolism in September 2022, and that paper is the primary structural reference. Eli Lilly's investor releases carry the trial data. ClinicalTrials.gov carries the registrations. These are verifiable in a way the chemical identifiers currently are not.

What this means practically

Treat the 4,731 Da figure as reported rather than verified, and be aware that a certificate quoting a different formula is not necessarily wrong. Mass spectrometry against whichever value a certificate claims is the only check available, and where a supplier and a reference source disagree there is no authoritative record to arbitrate between them.

Frequently asked questions

What is retatrutide's CAS number?

2381089-83-2 is the number commonly listed, though it does not resolve to a PubChem record.

Why is there no PubChem entry?

Not clear. Searches under the name, the development code and the CAS all return nothing, which is unusual for a compound at this stage of development.

Is CID 156588324 retatrutide?

No. That record is tirzepatide, its synonyms include Zepbound and LY3298176. It was cited in error here and has been removed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.